Vanguard Group
CSBR icon

Vanguard Group’s Champions Oncology CSBR Stock Holding History

Vanguard Group’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.31M Buy
334,605
+1,347
+0.4% +$8.97K ﹤0.01% 3517
2025
Q3 		$2.16M Buy
333,258
+6,229
+2% +$43.9K ﹤0.01% 3558
2025
Q2 		$2.41M Buy
327,029
+19,155
+6% +$135K ﹤0.01% 3475
2025
Q1 		$2.67M Buy
307,874
+872
+0.3% +$8.84K ﹤0.01% 3391
2024
Q4 		$2.63M Hold
307,002
– – ﹤0.01% 3484
2024
Q3 		$1.5M Hold
307,002
– – ﹤0.01% 3646
2024
Q2 		$1.59M Buy
307,002
+221,398
+259% +$1.08M ﹤0.01% 3636
2024
Q1 		$419K Buy
85,604
+2,767
+3% +$16.2K ﹤0.01% 4058
2023
Q4 		$466K Buy
82,837
+14,157
+21% +$79K ﹤0.01% 4054
2023
Q3 		$427K Buy
68,680
+673
+1% +$4.25K ﹤0.01% 4104
2023
Q2 		$434K Hold
68,007
– – ﹤0.01% 4162
2023
Q1 		$273K Hold
68,007
– – ﹤0.01% 4270
2022
Q4 		$307K Sell
68,007
-267,608
-80% -$1.75M ﹤0.01% 4218
2022
Q3 		$2.52M Sell
335,615
-10,228
-3% -$85.5K ﹤0.01% 3656
2022
Q2 		$2.77M Hold
345,843
– – ﹤0.01% 3668
2022
Q1 		$2.81M Buy
345,843
+2,710
+0.8% +$21.7K ﹤0.01% 3809
2021
Q4 		$2.87M Buy
343,133
+15,497
+5% +$143K ﹤0.01% 3894
2021
Q3 		$3.35M Hold
327,636
– – ﹤0.01% 3873
2021
Q2 		$3.37M Sell
327,636
-136,906
-29% -$1.39M ﹤0.01% 3787
2021
Q1 		$5.25M Buy
464,542
+32,371
+7% +$376K ﹤0.01% 3508
2020
Q4 		$4.66M Sell
432,171
-213,991
-33% -$2.21M ﹤0.01% 3390
2020
Q3 		$5.98M Buy
646,162
+251,822
+64% +$2.24M ﹤0.01% 3061
2020
Q2 		$3.77M Buy
394,340
+107,515
+37% +$916K ﹤0.01% 3218
2020
Q1 		$2.12M Buy
286,825
+21,637
+8% +$151K ﹤0.01% 3290
2019
Q4 		$2.21M Buy
265,188
+66
+0% +$407 ﹤0.01% 3423
2019
Q3 		$1.5M Hold
265,122
– – ﹤0.01% 3537
2019
Q2 		$2.08M Hold
265,122
– – ﹤0.01% 3468
2019
Q1 		$2.6M Buy
265,122
+14,011
+6% +$140K ﹤0.01% 3368
2018
Q4 		$1.96M Buy
251,111
+19,961
+9% +$229K ﹤0.01% 3383
2018
Q3 		$4.04M Buy
231,150
+78,428
+51% +$698K ﹤0.01% 3315
2018
Q2 		$984K Hold
152,722
– – ﹤0.01% 3694
2018
Q1 		$553K Buy
152,722
+43,669
+40% +$163K ﹤0.01% 3767
2017
Q4 		$423K Buy
109,053
+21,169
+24% +$75.5K ﹤0.01% 3786
2017
Q3 		$323K Buy
87,884
+13,052
+17% +$40K ﹤0.01% 3832
2017
Q2 		$194K Hold
74,832
– – ﹤0.01% 3908
2017
Q1 		$236K Buy
74,832
+26,581
+55% +$93K ﹤0.01% 3880
2016
Q4 		$122K Buy
48,251
+32,411
+205% +$63.1K ﹤0.01% 3959
2016
Q3 		$27K Buy
+15,840
New +$29.5K ﹤0.01% 4061

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Vanguard Group's CSBR Position: Q4 2025 in Review

Vanguard Group increased its Champions Oncology (CSBR) stake by 0.4% in Q4 2025, buying an estimated $8.97K and bringing the position to 334,605 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3517.

Vanguard Group first reported a position in CSBR in Q3 2016 and has held it in 38 quarters since. The position peaked at $5.98M in Q3 2020. 27 funds tracked by Wall St. Rank hold CSBR as of Q4 2025.

  • Vanguard Group held 334,605 shares of Champions Oncology worth $2.31M as of Q4 2025.
  • Vanguard Group bought 1,347 Champions Oncology shares in Q4 2025, an estimated $8.97K.
  • Champions Oncology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3517 holding.
  • Vanguard Group first reported a position in Champions Oncology in Q3 2016 and has held it in 38 quarters since.
  • Vanguard Group's Champions Oncology position peaked at $5.98M in Q3 2020.
  • 27 funds tracked by Wall St. Rank held Champions Oncology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.